AstraZeneca PLC (AZN)

NASDAQ: AZN · IEX Real-Time Price · USD
+0.69 (1.04%)
At close: Mar 23, 2023, 4:00 PM
+0.01 (0.01%)
After-hours: Mar 23, 2023, 4:16 PM EDT

Company Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines.

Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19.

The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.

It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153.

The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.

AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC
AstraZeneca logo
Country United Kingdom
Founded 1992
IPO Date May 12, 1993
Industry Drug Manufacturers - General
Sector Healthcare
Employees 83,100
CEO Pascal Soriot

Contact Details

1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge, X0 CB2 0AA
United Kingdom
Phone 011 44 20 7304 5000

Stock Details

Ticker Symbol AZN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000901832
CUSIP Number 046353108
ISIN Number US0463531089
SIC Code 2834

Key Executives

Name Position
Pascal Soriot D.V.M., M.B.A. Chief Executive Officer and Executive Director
Dr. Aradhana Sarin M.D. Chief Financial Officer and Executive Director
Marc Dunoyer Chief Executive Officer of Alexion and Chief Strategy Officer
Pam P. Cheng Executive Vice President of Operations and Information Technology and Member of External Sustainability Advisory Board
Chris Sheldon Head of Investor Relations
Jeffrey Pott Chief Human Resources Officer, General Counsel and Member of External Sustainability Advisory Board
Katarina Ageborg Executive Vice President of Sustainability, Chief Compliance Officer and Member of External Sustainability Advisory Board
Gonzalo Vina Head of Global Media Relations
Dr. Menelas Pangalos Ph.D. Executive Vice President of BioPharmaceuticals Research & Development and Member of External Sustainability Advisory Board
Dr. Ruud Dobber Ph.D. Executive Vice-President of BioPharmaceuticals Business Unit

Latest SEC Filings

Date Type Title
Mar 22, 2023 6-K Report of foreign issuer
Mar 22, 2023 6-K Report of foreign issuer
Mar 15, 2023 CERT Certification by an exchange approving securities for listing
Mar 13, 2023 8-A12B Registration of securities
Mar 9, 2023 6-K Report of foreign issuer
Mar 8, 2023 6-K Report of foreign issuer
Mar 8, 2023 6-K Report of foreign issuer
Mar 6, 2023 6-K Report of foreign issuer
Mar 3, 2023 6-K Report of foreign issuer
Mar 2, 2023 424B2 Prospectus